FDA gets power to block delay-tactic petitions, speeding generic drugs
H.R. 8908 — STOP GAMES Act of 2026 · Filed by Eric Sorensen (D-IL) · 1 cosponsor · Introduced May 19, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends FDA drug approval rules to let the agency deny petitions that appear designed primarily to delay generic or biosimilar drug approvals. It sets a 60-day filing deadline for petitions and gives the FDA authority to reject petitions that raise no valid scientific issues, are filed unreasonably late, are duplicative, or are timed to block competing applications. The bill aims to speed generic and biosimilar entry to market by preventing strategic delay tactics.
Why we flagged it
The bill's operative mechanism is to restrict brand-name pharmaceutical companies' ability to file strategic petitions that delay generic and biosimilar approvals. It does this by giving the FDA explicit authority to deny petitions whose primary purpose is delay, and by imposing a 60-day filing window. The functional effect is to accelerate generic/biosimilar market entry.
What the text implies
- The bill grants the FDA discretion to determine 'primary purpose' of delay without requiring proof of intent, creating risk that legitimate scientific petitions could be dismissed if filed close to approval dates or if the petitioner has not previously commented in public proceedings.
- Generic and biosimilar manufacturers may face reduced ability to challenge brand-name applications on scientific grounds if their petitions are deemed 'untimely' under the 60-day rule, even if new safety data emerges after that window.
The full analysis lists 3 implications of this text.
Who stands to gain
generic pharmaceutical manufacturers; biosimilar manufacturers; pharmacy benefit managers (via lower drug costs)